61 results about "Microvesicle" patented technology

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

The invention discloses a construction method of a human-derived HMC3 microglial cell line modified strain (named SIRT2-KD HMC3) for treating Alzheimer's disease (AD). The cell strain is obtained by knocking down an SIRT2 gene through genetic engineering. The invention also discloses a method for producing LEVs by using the cell strain, the cell strain can form an M2 anti-inflammatory form in a culture process, and the microvesicles LEVs-sh-SIRT2 are obtained by collecting a culture solution and adopting an ultra-high speed centrifugation method. A preclinical animal test (AD mode mouse APP / PS1) result shows that the LEVs prepared by the invention can effectively regulate and control inflammatory response and promote phagocytosis. After nasal administration, the LEVs can smoothly penetrate through a blood brain barrier to enter a hippocampus and are taken by microglial cells, so that chemotactic and phagocytic activities of the microglial cells are promoted, deposition of A beta in the brain is reduced, cognitive impairment of experimental animals is remarkably improved, and the medicine has a wide application prospect in the field of AD innovative treatment.

Disclosed herein are populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and / or prophylactic indications.

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by β-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.

The present application relates to the technical field of platelet exosome separation, and discloses a platelet exosome multistage laminar flow separation device, which comprises a liquid storage tank, a sleeve frame is symmetrically sleeved outside the liquid storage tank, a laminar flow box for laminar flow is arranged below the liquid storage tank, a first separation cabin for realizing primary separation is arranged below the laminar flow box, a second separation cabin for realizing resonance separation is arranged below the first separation cabin, a shunt box for shunting is arranged below the second separation cabin, and a plurality of collection tubes are arranged below the shunt box in an array, the present application realizes stable rectification of a sample and sheath liquid through the laminar flow box, the inertial force and the Dean force are utilized to accurately grade microvesicles, exosomes and cell fragments in combination with the gradually deepening spiral groove structure of the conical core in the first separation cabin, and the second resonance separation is performed on the exosomes through the resonance screens with different amplitudes and phase differences arranged in the second separation cabin, so that the enrichment purity of the exosomes is significantly improved.

The invention relates to the technical field of medical materials, in particular to a composition for soft tissue increment and a preparation method thereof, and the composition for soft tissue increment comprises a plasma matrix compressed material and a microvesicle concentrated solution. The composition for soft tissue increment provided by the invention comprises a plasma matrix compressed material and a microvesicle concentrated solution, the plasma matrix compressed material is rich in effective substances such as platelets and immune cells, has a compact three-dimensional fibrous protein network structure, and can provide a required scaffold for soft tissue regeneration, so that the soft tissue regeneration effect is improved. The microvesicle concentrated solution contains a large number of effective biological components such as cell factors and signal molecules, regeneration of local soft tissue can be further regulated and controlled, the microvesicle concentrated solution and the microvesicle concentrated solution have a synergistic effect, the excellent soft tissue regeneration promoting capacity is achieved, a complete autologous source is achieved, connective tissue transplantation surgery is replaced, and the application prospect is wide. The excellent performance is shown in the clinical application of soft tissue regeneration.

The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a method for preparing a nanocomposite carrying PDGF-BB mRNA, the preparation method comprising: 1) preparing LNP carrying PDGF-BB mRNA: quickly mixing a lipid phase containing 7C1 cationic liposomes with an aqueous phase containing PDGF-BB mRNA to obtain LNPmRNA; 2) preparing a PLGA gas core core by a double emulsion method; 3) mixing the PLGA gas core core in step 2) with the LNPmRNA in step 1), and standing to obtain a LNPmRNA@PLGA nanocomposite. The LNPmRNA@PLGA nanocomposite of the present invention has the advantages of protection, targeting, visibility and responsiveness. It is combined with in vitro focused ultrasound, which can not only realize the visual delivery of drugs, but also qualitatively and semi-quantitatively evaluate the neovascularization in advanced atherosclerotic plaques, and improve the cell transfection efficiency under the targeted microbubble destruction effect of in vitro focused ultrasound, accurately and efficiently overexpress the target protein, achieve the goal of drug treatment, and reduce systemic toxic side effects.

Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.

The application belongs to the technical field of exosome processing, and discloses an exosome microvesicle nondestructive separation and purification device, which comprises a sealed separation box, a laminated assembly is arranged in the inner cavity of the sealed separation box, the laminated assembly is sleeved outside a central shaft assembly, a pressure plate is arranged at the top end of the laminated assembly, and a synchronous driving assembly is arranged. When in the compressed state, the micro-nano groove forms a precise nanoscale channel for interception and filtration, and when in the relaxed state, the elastic sheet rebounds rapidly with the release of the axial pressure, the cross-sectional geometry of the micro-nano groove is deformed, the periodic geometric deformation breaks the mechanical stability of the filter cake layer from the physical level, the particles originally stuck in the groove or adsorbed on the surface lose the clamping force instantaneously, and are automatically detached from the surface fluid under the shearing action of the surface fluid, so that the flux decay rate of the device is controlled at a small value under long-time operation, and continuous and stable filtration in the true sense is realized.

The invention discloses a stem cell-based microvesicle as well as a preparation method and application thereof, belongs to the technical field of biological tissue engineering, and particularly relates to a preparation method of the stem cell-based microvesicle, which comprises the following steps: culturing stem cells until the cell fusion degree is 80-90%, performing hypoxia treatment, and cleaning for 2-3 times; standing and culturing the cleaned stem cells, then adding a calcium ion carrier, and carrying out ultrasonic treatment; the serum-free basic culture medium containing the calcium ion carrier is immediately absorbed and removed, the cells are cleaned through PBS, culture is conducted for 24 h, and cell supernatant is collected and merged respectively; performing first centrifugation to remove cell debris; performing second centrifugation to remove dead cells and large cell debris; carrying out third centrifugation to remove organelles; fourth centrifugation is carried out, large vesicles are removed, and a final supernatant is obtained; and filtering and centrifuging to obtain a microvesicle precipitate. The preparation method of the microvesicles aims at systematically improving the yield and biological activity of the stem cell microvesicles through low-oxygen pre-stimulation, ultrasonic-calcium ion carrier synergistic induction and differential centrifugation.

To provide a freeze-dried composition that yields an ultrasound contrast agent upon reconstitution, and a method for preparing the same.SOLUTION: A freeze-dried composition comprising an amphiphilic material and a freeze-drying protecting component, which, upon reconstitution with a pharmaceutically acceptable solution in the presence of a biocompatible gas, provides a suspension of calibrated gas-filled microvesicles, wherein the reconstituted suspension of microvesicles has a geometric standard deviation (GSD) value of at least 1.22 or lower.SELECTED DRAWING: Figure 1

The invention relates to the field of agricultural microbial technology and soil remediation, in particular to application of microvesicle bacteria and a microbial agent thereof in saline-alkali soil, the name of the microvesicle bacteria is Microbulbifer sp.PM1, the preservation unit is China Center for Type Culture Collection, the preservation acceptance date is January 4, 2026, and the preservation number is CGMCC NO: 37273. Through tests and determination, the microbial agent prepared from the PM1 has important application value in the field of saline-alkali soil improvement, especially in high-quality and yield-increasing cultivation of corn.

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

The present invention belongs to the technical field of nanomaterial science and specifically relates to a magnetic nanocomposite with adjustable magnetic properties and a preparation method thereof. First, an iron oleate complex precursor is prepared, then oleic acid-coated iron oxide nanoparticles are prepared, and then citric acid-coated iron oxide nanoparticles (NPs) are prepared. By collecting cell microvesicles and combining with the electroporation technology, the magnetic nanomaterials are transferred into the interior of the vesicles. By adjusting the electroporation voltage, the loading amount of the magnetic nanoparticles is regulated to construct a magnetic nanocomposite with adjustable magnetic properties. Moreover, the preparation method is simple to operate, does not require large-scale equipment during the process, has low requirements for the professionalism of the operators, and the prepared magnetic nanocomposite has good biological safety and good application prospects.

This application provides a biomimetic self-driven microvesicle, its preparation method, and its application, belonging to the field of nanobiodelivery technology. This application utilizes a triple synergistic mechanism of a hybrid biomimetic membrane, a magneto-electro-thermal responsive core, and a pH / H2S dual-response release. Driven by a gradient rotating magnetic field generator, the near-infrared photothermal modulation unit softens the cell membrane through thermal effects, and a focused femtosecond pulsed electric field module forms reversible ultrapores. This allows the biomimetic self-driven microvesicles to precisely pass through the reversible ultrapores, then migrate and accumulate deep within the target cell membrane, significantly improving transmembrane efficiency and reducing non-specific damage. This makes it suitable for high-end applications such as deep tumor treatment, blood-brain barrier penetration, and oral delivery of biological drugs.

This invention relates generally to ARRDC1 fusion proteins, ARRDC1-mediated microvesicles (ARMMs) degrading systems, and their uses.

The invention provides a microvesicle-loaded DC vaccine as well as a preparation method and application thereof, DC is taken as a carrier, microvesicles are loaded, and the DC-loaded microvesicles are derived from hepatoma carcinoma cells Hepa1-6; the preparation method comprises the following steps: (1) culturing liver cancer Hepa1-6 cells, exposing the cells in an ultraviolet environment for irradiation, then collecting cell supernatant, and extracting MPs; (2) obtaining bone marrow single cells, firstly inducing the bone marrow single cells into imDC (imDC), and then inducing the bone marrow single cells into mature DC (mDC); and (3) incubating the DC and the MPs to obtain the DC vaccine loaded by the microvesicles. The invention also discloses an application of the DC vaccine loaded by the microvesicles in preparation of drugs or preparations for treating liver cancer. The DC vaccine loaded by the microvesicles can promote the activation of CD8 + T cells and the killing ability to liver cancer cells. According to the present invention, the liver cancer cells can be specifically killed without damaging other tissues, the specific recognition and killing function of the T cells on the tumor cells can be enhanced, and the tumor immune escape can be easily overcome.

The present disclosure relates to methods of identifying and treating kidney rejection in a subject comprising analyzing RNA, including microvesicular RNA.

The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a mixture of freeze-drying protecting components, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.

The present invention relates to the manufacture of a freeze-dried product for the preparation of a suspension of aerated microvesicles, and to a suspension of aerated microvesicles prepared by reconstitution of the freeze-dried precursor with a physiologically acceptable liquid carrier in the presence of a physiologically acceptable gas. According to the invention, a freeze-dried product is obtained by freeze-drying the emulsion formulation in batches.

This invention discloses the application of urinary microvesicle proteins as diagnostic markers for renal cell carcinoma. The protein markers derived from urinary extracellular vesicles associated with clear cell renal carcinoma are characterized by being selected from one or more of the following proteins: CSPG4, AQP1, PLIN2, CA9, and HAVCR1. The invention also describes the application of reagents for detecting these protein markers in the preparation of auxiliary diagnostic reagents for clear cell renal carcinoma. The inventors, using flow cytometry, analyzed 200 patients and found that five proteins derived from urinary extracellular vesicles could effectively distinguish patients with clear cell renal carcinoma from controls (including healthy individuals, patients with benign renal tumors, patients with benign renal cysts, and patients with chronic kidney disease).

The application relates to an anti-impact PE pipe and a preparation method thereof, and belongs to the technical field of polymer composite materials. The components of the PE pipe are as follows: calcium carbonate whiskers 6.2-9.5 wt%, an anti-impact modifier 4.4-5.8 wt%, a lubricant 0.2-0.3 wt%, an antioxidant 0.15-0.2 wt%, an ultraviolet absorber 0.11-0.14 wt% and color master granules 2.6-3.2 wt%, and the balance is polyethylene resin. The disulfide structure in the molecular chain of the anti-impact modifier is loaded between the calcium carbonate whiskers in the form of multi-point anchoring through chelation to form a reinforcing and impact energy dispersion network, meanwhile, the polycyclohexyl segment in the molecular chain forms a large number of "microvesicle" unit structures on the surface of the calcium carbonate whiskers, absorbs impact energy and uniformly disperses and transitions the impact energy through the slippage deformation of the vesicle structure, and the anti-impact performance of the PE pipe is effectively improved.

To provide stem cells and exosome compositions having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.SOLUTION: The invention provides an exosome or microvesicle selected from among an iPSC cell, an embryonic stem cell, and a stem cell that has been contacted with an effective amount of an isoxazole compound, a derivative or equivalent thereof, or Danazol, where the exosome or microvesicle overexpresses one or more of: a) a microRNA (miRNA) selected from among mir-373, mir-210, mir-377, mir-367, mir-520, mir-548ah, mir-335, mir-21, mir-30c, mir-214 and mir-548q; and / or b) one or more proteins selected from among Tsg101, CD9, Hsp70, Flotillin-1 and GAPDH.SELECTED DRAWING: None

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.

Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-vesicle from the cell, wherein the micro-vesicle includes the target protein. Also provided are cells, reagents and kits that find use in making the micro-vesicles, as well as methods of using the micro-vesicles, e.g., in research and therapeutic applications.

Provided is a method for promoting generation of a mitochondria-containing microvesicle and a treating method thereof. Specifically, provided is a method for promoting generation of the mitochondria-containing microvesicle with a combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor. Also provided is a method for generating an extracellular vesicle composition, comprising: co-culturing cells having mitochondria with the mitochondrial generation promoting factor and the extracellular vesicle generation promoting factor to obtain the extracellular vesicle composition rich in the mitochondria-containing microvesicle. Adding the above factors may promote the cells to generate the mitochondria-containing microvesicle. The collected mitochondria are encapsulated by the microvesicle, and therefore can be easily stored and transferred into the cells. Also provided are an isolated extracellular vesicle composition, a pharmaceutical composition comprising the same, and a method for treating diabetes and / or renal injury by administering a medicine comprising the same.

The present invention provides the use of non-inflammatory microvesicles secreted by macrophages induced by β-glucan in the treatment of inflammation, relating to microvesicles secreted by macrophages induced by β-glucan, products that can be prepared from the microvesicles, and their uses. The microvesicles provided by the present invention can inhibit M1 polarization of macrophages and the secretion of inflammatory factors in cells, thereby reducing inflammation.

A system for providing microvesicles, in particular microvesicles, having a predefined size and / or size distribution, the system comprising:-means (150) for receiving microvesicles in a microvesicle carrier liquid to obtain a heterogeneous mixture comprising microvesicles; -a holding unit (140) for holding a heterogeneous mixture comprising microvesicles, the heterogeneous mixture comprising microvesicles and a microvesicle carrier liquid, in particular a salt solution; -a homogenization mechanism (160) arranged for homogenizing the heterogeneous mixture comprising the microvesicles held in the holding unit; -an auxiliary reservoir (180) containing a microvesicle carrier liquid, in particular a salt solution, where the auxiliary reservoir is arranged in fluid connection with the holding unit.

The present invention discloses urine microvesicle proteins related to lung cancer and their applications. The application of a reagent for detecting protein markers derived from urine extracellular vesicles in the preparation of a reagent for the auxiliary diagnosis of lung cancer, wherein the protein markers derived from urine extracellular vesicles are selected from any one or more of the following proteins: TRAP1, MAPK1IP1L, STOM, LAP3, FGB, SLC5A2, RAB33B, STX7, CAPZA2, RAB15. The protein markers of the present invention can effectively distinguish lung cancer patients and healthy individuals from patients with benign lung nodules. Generally speaking, the proteins in urine extracellular vesicles can be used as detection markers for the diagnosis, staging and prognosis of lung cancer.